We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-9.48%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.06B
AUM Growth
-$340M
Cap. Flow
-$46.6M
Cap. Flow %
-2.26%
Top 10 Hldgs %
68.62%
Holding
39
New
2
Increased
10
Reduced
9
Closed
–

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$6.61M
2
PBYI icon
Puma Biotechnology
PBYI
+$5.18M
3
IMMU
Immunomedics Inc
IMMU
+$4.44M
4
FOLD
Amicus Therapeutics
FOLD
+$2.24M
5
ABMD
Abiomed Inc
ABMD
+$2.04M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$26.5M
2
CELG
Celgene Corp
CELG
+$15.1M
3
SAGE
Sage Therapeutics
SAGE
+$10.7M
4
UTHR icon
United Therapeutics
UTHR
+$7.41M
5
ALGN icon
Align Technology
ALGN
+$5.41M

Sector Composition

Rank Sector Weight
1 Healthcare 89.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$12.4B
$223M 10.85%
2,606,485
-35,000
-1% -$2.99M
INSM icon
2
Insmed
INSM
$28.6B
$202M 9.82%
7,890,917
+237,300
+3% +$6.61M
ABMD
3
DELISTED
Abiomed Inc
ABMD
$184M 8.95%
706,354
+7,700
+1% +$2.04M
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$146M 7.08%
795,031
-62,650
-7% -$10.7M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$134M 6.52%
1,023,780
-205,250
-17% -$26.5M
STAA icon
6
STAAR Surgical
STAA
$1.21B
$124M 6.05%
4,237,051
+18,149
+0.4% +$524K
UTHR icon
7
United Therapeutics
UTHR
$23.1B
$121M 5.89%
1,552,792
-79,233
-5% -$7.41M
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
$97.3M 4.73%
7,796,299
+176,466
+2% +$2.24M
IMMU
9
DELISTED
Immunomedics Inc
IMMU
$92.6M 4.5%
6,676,755
+295,200
+5% +$4.44M
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$87M 4.23%
6,935,074
– –
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
$82.6M 4.02%
2,771,394
– –
AIMT
12
DELISTED
Aimmune Therapeutics
AIMT
$79.7M 3.88%
3,828,564
+79,625
+2% +$1.64M
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
$76.5M 3.72%
5,141,304
-98,000
-2% -$1.77M
VNDA icon
14
Vanda Pharmaceuticals
VNDA
$302M
$71.2M 3.46%
5,055,050
– –
ACAD icon
15
Acadia Pharmaceuticals
ACAD
$5.03B
$61.7M 3%
2,308,803
+60,400
+3% +$1.54M
ALGN icon
16
Align Technology
ALGN
$12.3B
$40.4M 1.96%
147,505
-17,900
-11% -$5.41M
EXAS
17
DELISTED
Exact Sciences
EXAS
$37.2M 1.81%
314,889
– –
AMAG
18
DELISTED
AMAG Pharmaceuticals
AMAG
$33.7M 1.64%
3,375,506
-45,800
-1% -$494K
KPTI icon
19
Karyopharm Therapeutics
KPTI
$48M
$31.5M 1.53%
350,818
– –
MNTA
20
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$23.9M 1.16%
1,919,313
+77,700
+4% +$1.03M
ALDR
21
DELISTED
Alder Biopharmaceuticals
ALDR
$21.9M 1.07%
1,861,630
– –
PBYI icon
22
Puma Biotechnology
PBYI
$454M
$17.9M 0.87%
1,405,680
+224,900
+19% +$5.18M
GILD icon
23
Gilead Sciences
GILD
$165B
$11.9M 0.58%
175,900
– –
PRTA icon
24
Prothena Corp
PRTA
$450M
$11.7M 0.57%
1,108,510
– –
RIGL icon
25
Rigel Pharmaceuticals
RIGL
$750M
$10.4M 0.51%
398,595
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q2 2019 Portfolio in Review

As of Q2 2019, Palo Alto Investors held 39 positions worth $2.06B, down 14% from $2.4B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Palo Alto Investors's Q2 2019 filing shows 2 new, 10 increased and 9 reduced positions. Its largest new stake was Aldeyra Therapeutics: 73,500 shares worth $441K. The largest sale was Alexion Pharmaceuticals, an estimated $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier.

  • Palo Alto Investors's largest Q2 2019 buy was Aldeyra Therapeutics: 73,500 shares worth $441K.
  • Palo Alto Investors added most to Insmed in Q2 2019, an estimated $6.61M increase.
  • Palo Alto Investors's biggest Q2 2019 reduction was Alexion Pharmaceuticals, cutting an estimated $26.5M.
  • Palo Alto Investors's ten largest holdings make up 69% of its $2.06B portfolio in Q2 2019.
  • Palo Alto Investors opened 2 new positions and closed 0 in Q2 2019.
  • Palo Alto Investors's portfolio value fell 14% quarter-over-quarter to $2.06B.

Based on Palo Alto Investors's 13F filing for Q2 2019, filed 14 Aug 2019.